Despite increased insight on skin cancer risk factors, the incidence continues to rise worldwide. This review article summarizes new treatment options available, which help to redefine and expand the diagnosis of advanced BCC and allow dermatologists to offer more effective therapy to a broader population.
The largest-ever vismodegib study in advanced basal cell carcinoma, the STEVIE study, confirms pivotal study findings in a real-world setting, helping dermatologists to provide a complete palette of skin cancer treatments.
GlobalMed has represented medical and aesthetic dermatology brands, including BMT, CoolTouch and Radiancy, since 1996. Omnilux noninvasively treats dermatologic conditions, including acne, fine lines and wrinkles and non-melanoma skin cancer.
New technologies for managing skin cancer were a topic of discussion at a scientific session at the American Society for Dermatologic Surgery’s 2015 annual meeting in Chicago in October. Seaver L. Soon, M.D., division of dermatology and dermatologic surgery at Scripps Clinic, La Jolla, Calif., was one of the moderators for the scientific discussion titled, “The Cutting Edge: New Technologies for Managing Skin Cancer.” Learn more
Immunosuppressed patients have a greater risk for developing high-risk non-melanoma skin cancer, which can typically be more aggressive in this patient population. As such, a multidisciplinary approach is required when contemplating appropriate treatment and management of this patient population.
A newly approved medication called sonidegib (Odomzo) gives physicians a second option in a class of medications designed to treat a small number of patients who suffer from locally advanced basal cell carcinoma and meet other criteria. Learn more
Due to the complexities and follow-up requirements of nonsurgical treatments for skin cancer, patient selection is critical. Expert offers tips for using various noninvasive treatment options for BCC, SCC, and melanoma.